Drug Type Small molecule drug |
Synonyms NOV-1401 (National OncoVenture), IDX 1197 HCL, IDX-1197 + [4] |
Target |
Action inhibitors |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC23H23FN4O2 |
InChIKeyYNBQAYKYNYRCCA-UHFFFAOYSA-N |
CAS Registry1681017-83-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced gastric carcinoma | Phase 2 | United States | 28 Jun 2021 | |
Advanced gastric carcinoma | Phase 2 | China | 28 Jun 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 29 Aug 2017 | |
Solid tumor | Phase 1 | South Korea | 29 Aug 2017 | |
Breast Cancer | Clinical | South Korea | - | |
Stomach Cancer | IND Approval | China | 07 Dec 2021 |
Phase 1/2 | Hypoparathyroidism-Retardation-Dysmorphism Syndrome | Metastatic Gastric Carcinoma HRD gene mutations | BRCA1 | BRCA2 ... View more | 43 | Venadaparib plus irinotecan | cwgttcnilv(jjxhdjwxah) = oexulljrtq scnexxukbp (fycnhikgcd ) View more | Positive | 30 May 2025 | |
(HRD gene mutations) | cwgttcnilv(jjxhdjwxah) = qhddqfqtqb scnexxukbp (fycnhikgcd ) View more | ||||||
Phase 1 | 32 | zvfxsyzhul(bpdccjnxfq) = Not observed up to 240 mg/d. iihmyouhvf (cotbmohbfn ) View more | Positive | 01 Feb 2025 | |||
Phase 1 | Metastatic Gastric Carcinoma HRD gene mutations | 26 | Venadaparib plus irinotecan | mghnhlolvb(viqjsvafjx) = zgisrniovl vjrwkbjlle (zmpbzwwkqw ) View more | Positive | 24 May 2024 | |
Placebo plus irinotecan | yrucqurrxm(hscrdnpfmg) = xulzncmgdf qjseqzqwoj (lqaqcazlii, 2.9 - 5.5) | ||||||
NCT04174716 (ASCO2023) Manual | Phase 1 | Pancreatic Cancer ASXL1 Mutation | ATM Mutation | 8 | (ATMmASXL1m) | vxgbmwiapg(fhhykfkdph) = rruzoxhdhg eeqjwtbfro (jitdvbysea ) View more | Positive | 31 May 2023 |
(ATMmASXL1wt) | vxgbmwiapg(fhhykfkdph) = yrdcmkcaap eeqjwtbfro (jitdvbysea ) View more | ||||||
Phase 1/2 | 14 | jxyxjxhtsn(nzvbgolzkf) = 8/14 (57%) uaynnbtjkt (tfybnftypr ) View more | - | 16 Sep 2021 | |||
Phase 1 | 32 | lpovpityyl(cheqhgyfxd) = Frequently observed adverse drug reactions were as follows – Anemia (56%), nausea (38%) and neutropenia (25%). armlukvzmz (pjyeyvfnrd ) | Positive | 20 May 2021 | |||
(BRCAm(+)) |